FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2592076641> ?p ?o ?g. }

• W2592076641 endingPage "1929" @default.
• W2592076641 startingPage "1929" @default.
• W2592076641 abstract "Abstract Abstract 1929 Background: Allogeneic hematopoietic cell transplantation (HCT) is associated with inferior outcomes in patients with more advanced stage AML. In such cases, reducing the ablative intensity of the preparative regimen could potentially compromise its efficacy. We hereby compare transplant outcomes of two preparative regimens, known as FB2 and FB4, in patients (pts) with AML transplanted in second complete remission (CR2) or beyond at EBMT participating centers. Materials and methods: Between 2003 and 2010, 128 (FB2=88 (69%), FB4=40 (31%)) pts with a median age of (FB2=60 (22–70) years, FB4=42 (19–65) years, p<0.0001), with AML in ≥CR2 (FB2 (CR2=85 (97%), CR3=3 (3%)); FB4 (CR2=38 (95%), CR3=2 (5%)), p=0.67, underwent allogeneic HCT. FB2 comprised intravenous (IV) busulfan cumulative dose of 6.4 ± 10% mg/kg, while FB4 cumulative dose was 12.8 ± 10% mg/kg. Cytogenetic risks groups were similar: FB2 (good=17, int=31, poor=6) and FB4 (good=6, int=7, poor=0), p=0.35. For pts treated with FB2, donor source consisted of matched-related donors (MRD)=32, matched unrelated donor (MUD)=39, mismatched unrelated donors (MMUD)=8, unknown=9. For FB4, donor source consisted of MRD=17, MUD=15, MMUD=6, unknown=2. Use of peripheral blood stem cells (PBSC) was higher in the FB2 group (92% vs. 70%, p=0.001). Administration of anti-thymocyte globulin (ATG) was also higher in FB2 conditioned patients (89% vs. 45%, p<0.0001). Results: Median follow-up time was 24 (3–76) months. Median time to absolute neutrophil count engraftment (days) was 16 (5–38) and 16 (9–29) days, for FB2 and FB4, respectively (p=0.45). The 2-year leukemia-free survival (LFS), cumulative incidence of relapse (CI-R), and of non-relapse mortality (NRM) was: LFS (FB2=47±5% vs. FB4=70±8%, p=0.01), CI-R (FB2=27±5% vs. FB4=19±7%, p=0.24), and NRM (FB2=25±5% vs. FB4=10±5%, p=0.06). The 2-year cumulative incidence of chronic GVHD was similar (FB2=41±6% vs. FB4=43±8%, p=0.8). On multivariable analysis, favorable impact on 2-year LFS was observed with FB4 conditioning (HR 0.66 (95%CI: 0.46–0.97), p=0.03) and with longer interval from diagnosis to transplantation (> median) (HR=0.49 (95%CI: 0.29,0.85), p=0.01). When the analysis was performed by age groups, the statistical advantage of FB4 on LFS was lost, likely because of small numbers in each subgroup. Indeed, for pts <50 yrs. (n=43; FB2=16, FB4=27), LFS was (FB2=50±13% vs. FB4=72±9%, p=0.11), whereas for pts ≥50 yrs. (n=85, FB2=72, FB4=13), LFS was (FB2=47±6% vs. FB4=67±13%, p=0.18). Conclusion: Although limited by the small number of patients, these results suggest that FB4 is a reasonable preferred conditioning in patients with AML in ≥CR2. Disclosures: No relevant conflicts of interest to declare." @default.
• W2592076641 created "2017-03-16" @default.
• W2592076641 creator A5001646221 @default.
• W2592076641 creator A5008084507 @default.
• W2592076641 creator A5011772396 @default.
• W2592076641 creator A5014705544 @default.
• W2592076641 creator A5015832963 @default.
• W2592076641 creator A5017327825 @default.
• W2592076641 creator A5020116063 @default.
• W2592076641 creator A5022161221 @default.
• W2592076641 creator A5022435499 @default.
• W2592076641 creator A5030282008 @default.
• W2592076641 creator A5032928140 @default.
• W2592076641 creator A5040417184 @default.
• W2592076641 creator A5058925624 @default.
• W2592076641 creator A5059779561 @default.
• W2592076641 creator A5069084023 @default.
• W2592076641 date "2012-11-16" @default.
• W2592076641 modified "2023-10-17" @default.
• W2592076641 title "Significance of Busulfan Dose Intensity On Outcomes of Hematopoietic Cell Allografting for AML in Second Complete Remission or Beyond: A Report From the EBMT Acute Leukemia Working Party" @default.
• W2592076641 doi "https://doi.org/10.1182/blood.v120.21.1929.1929" @default.
• W2592076641 hasPublicationYear "2012" @default.
• W2592076641 type Work @default.
• W2592076641 sameAs 2592076641 @default.
• W2592076641 citedByCount "0" @default.
• W2592076641 crossrefType "journal-article" @default.
• W2592076641 hasAuthorship W2592076641A5001646221 @default.
• W2592076641 hasAuthorship W2592076641A5008084507 @default.
• W2592076641 hasAuthorship W2592076641A5011772396 @default.
• W2592076641 hasAuthorship W2592076641A5014705544 @default.
• W2592076641 hasAuthorship W2592076641A5015832963 @default.
• W2592076641 hasAuthorship W2592076641A5017327825 @default.
• W2592076641 hasAuthorship W2592076641A5020116063 @default.
• W2592076641 hasAuthorship W2592076641A5022161221 @default.
• W2592076641 hasAuthorship W2592076641A5022435499 @default.
• W2592076641 hasAuthorship W2592076641A5030282008 @default.
• W2592076641 hasAuthorship W2592076641A5032928140 @default.
• W2592076641 hasAuthorship W2592076641A5040417184 @default.
• W2592076641 hasAuthorship W2592076641A5058925624 @default.
• W2592076641 hasAuthorship W2592076641A5059779561 @default.
• W2592076641 hasAuthorship W2592076641A5069084023 @default.
• W2592076641 hasConcept C126322002 @default.
• W2592076641 hasConcept C141071460 @default.
• W2592076641 hasConcept C2776694085 @default.
• W2592076641 hasConcept C2776755627 @default.
• W2592076641 hasConcept C2777408962 @default.
• W2592076641 hasConcept C2779263901 @default.
• W2592076641 hasConcept C2780611847 @default.
• W2592076641 hasConcept C2781413609 @default.
• W2592076641 hasConcept C2911091166 @default.
• W2592076641 hasConcept C71924100 @default.
• W2592076641 hasConcept C88879693 @default.
• W2592076641 hasConcept C90924648 @default.
• W2592076641 hasConceptScore W2592076641C126322002 @default.
• W2592076641 hasConceptScore W2592076641C141071460 @default.
• W2592076641 hasConceptScore W2592076641C2776694085 @default.
• W2592076641 hasConceptScore W2592076641C2776755627 @default.
• W2592076641 hasConceptScore W2592076641C2777408962 @default.
• W2592076641 hasConceptScore W2592076641C2779263901 @default.
• W2592076641 hasConceptScore W2592076641C2780611847 @default.
• W2592076641 hasConceptScore W2592076641C2781413609 @default.
• W2592076641 hasConceptScore W2592076641C2911091166 @default.
• W2592076641 hasConceptScore W2592076641C71924100 @default.
• W2592076641 hasConceptScore W2592076641C88879693 @default.
• W2592076641 hasConceptScore W2592076641C90924648 @default.
• W2592076641 hasIssue "21" @default.
• W2592076641 hasLocation W25920766411 @default.
• W2592076641 hasOpenAccess W2592076641 @default.
• W2592076641 hasPrimaryLocation W25920766411 @default.
• W2592076641 hasRelatedWork W1955322177 @default.
• W2592076641 hasRelatedWork W2142338120 @default.
• W2592076641 hasRelatedWork W2360634842 @default.
• W2592076641 hasRelatedWork W2414700771 @default.
• W2592076641 hasRelatedWork W3002680405 @default.
• W2592076641 hasRelatedWork W3031569017 @default.
• W2592076641 hasRelatedWork W3174720739 @default.
• W2592076641 hasRelatedWork W3196871566 @default.
• W2592076641 hasRelatedWork W3205044970 @default.
• W2592076641 hasRelatedWork W4315498210 @default.
• W2592076641 hasVolume "120" @default.
• W2592076641 isParatext "false" @default.
• W2592076641 isRetracted "false" @default.
• W2592076641 magId "2592076641" @default.
• W2592076641 workType "article" @default.